For 30 advance/early chapters : p atreon.com/AutumnXd
Jaeger Program
Target Spec: Two-hundred-and-fifty-foot, seventeen-hundred-ton humanoid combat mech. Construction documentation includes the following completed subsystem packages:
Liquid Neural Multi-Pilot Connection Technology (Production-Ready)
Multi-Lobed Plasma Cannon Technology (Production-Ready)
Trinity Horizon Gateway Operating System (Design Complete)
Midnight-9 Toroidal Power Core (Design Complete)
[Eighty-seven additional subsystem packages listed below...]
The Aegis expert panel stared at the document index.
At first glance, the file looked similar to the proposal they'd reviewed months ago. Same project name. Same conceptual targets. Same technologies listed.
But each technology in the table of contents was followed by a status tag that hadn't existed in the original proposal.
"Production-Ready."
"Design Complete."
The reviewers looked at each other. Each of them understood what those four-word phrases meant. None of them were ready to believe what they meant.
"Click into one. Let's see what's actually there."
The panel chair clicked through the title page and into the first subsystem documentation.
Trinity Horizon Gateway Operating System.
The page jumped to a hierarchical index that filled the screen. Sub-section after sub-section, each one labeled with technical specificity that the chair could feel was at production-grade depth even before opening any individual document.
He clicked one at random.
Dense technical content filled the display. Detailed engineering notes. Block diagrams. Code architecture maps. Data flow charts. Parameter tables. Specifications that read like a working operating system manual rather than a research proposal.
This wasn't an outline. This wasn't a feasibility study. This was implementation documentation.
"Next subsystem. Quick."
The panel members were on the edge of their seats now. The chair backed out to the master index and selected another entry.
Mech Underwater Seal System.
Another hierarchical drill-down. Another wall of detailed technical content. The opening overview specified the system's design parameters: maintained pressure seal at depths down to seven thousand meters, hybrid static and dynamic sealing architecture, redundant secondary seals at all primary articulation points.
"Seven thousand meters," one of the reviewers said quietly. "That's deeper than most submarines operate at."
"And multi-layer redundancy means it can survive impact damage during operation. Even if the primary seal fails, the secondary and tertiary layers maintain integrity."
"This is submersible engineering. At Jaeger scale. Why does a combat mech need to operate at seven thousand meters?"
"Did anyone ask him this?"
The room was quiet. Nobody had asked Ryan about the operational depth specification. Everyone had assumed the mech would operate primarily on land, with limited shoreline and shallow-water capability. The seven-thousand-meter rating was beyond anything they'd anticipated.
The reviewers had done their homework on mechs from popular culture in preparation for this project, since none of them had backgrounds in giant-robot engineering. Mechs in films and animated series typically operated on land or in space. Crimson Typhoon was apparently designed for an entirely different domain: deep ocean. The depth rating put the design firmly in the category of "specialized for environments where no other military platform can operate."
The implications cascaded. A combat platform capable of operating at seven thousand meters wasn't competing with land-based forces. It was operating in a strategic envelope that effectively didn't exist yet. Submarine forces had ceilings of approximately a thousand meters for combat-rated platforms. Crimson Typhoon's specification was seven times that.
If the mech could actually achieve this depth rating, the technology underlying it would transform underwater operations across every domain. Civil submarines, deep-sea infrastructure, military submersibles, oil and gas drilling. The seal system alone was worth more than the entire mech program.
"Continue. Next subsystem."
The chair clicked through the structured index.
Each subsystem followed the same pattern: full specifications, complete drawings, materials lists, fabrication procedures, integration plans. The package wasn't a research proposal asking for development funding. The package was a manufacturer's brief asking for production resources.
After several hours of skimming, the panel had reached a consensus they hadn't been prepared for.
"This is buildable," one of the senior reviewers said finally. "I have no idea how he got from concept to construction documentation in this timeframe, but if these specifications are accurate, this thing can be built."
"We need to validate the specifications. Each subsystem needs independent technical review by domain specialists."
"That's going to take months."
"The chairman is going to want a recommendation faster than that."
The chair closed his eyes briefly. He'd been on this panel for fifteen years. He'd reviewed many large engineering proposals across that time. He'd never seen a single proposer deliver this much rigorous documentation. The depth and breadth of the package suggested an organization of hundreds of specialized engineers working for years.
Ryan Mercer was one teenager. Working for, what, eight months at this scale?
The senior reviewer rubbed his temples and called for the chairman's executive assistant.
"Tell him we have something he needs to see. And brief him before he reviews. He's going to need preparation time."
Meanwhile, several hundred miles away, James Alcott was on his fifth phone call of the morning.
"Are you sure you want to withdraw at this stage? Angel has actually received favorable reviews in international markets. The tactile feedback technology is genuinely advanced. The medical-grade applications for our prosthetic remain promising."
The line went dead.
Alcott looked at his phone, then placed it face-down on his desk.
That was the fourth investor in two days to terminate their commitment.
He leaned back in his chair and exhaled slowly.
The two months since Triton-1's launch had been a slow, grinding nightmare. Helios's Angel product, launched the same day as Triton-1, had suffered catastrophic comparative damage in the public reception. Tactile feedback didn't save them. Surgical requirement didn't save them. Premium positioning didn't save them. Triton-1 was simply on a different technology curve, and Helios couldn't catch up.
NeuraPath, Alcott's company, had been pursuing the same technology path as Helios. Surgery-based, targeted muscle reinnervation. The technology path that had just been demonstrated to be obsolete.
For weeks, Alcott had been managing investor relations alone. The early-stage investors who had funded NeuraPath's initial development were still committed, at least nominally. But the later-stage investors who had come in based on the surgical-prosthetic market opportunity were exiting in waves. Each call from a panicked institutional investor was followed by a quiet meeting with legal counsel about contract obligations.
Most of the exit clauses were enforceable. Most of the investors who wanted out were going to get out. NeuraPath's runway was shrinking rapidly.
The original problem had been that Triton-1 was better and cheaper. The follow-on problem was that with Helios crashing, every comparable surgical-prosthetic company was being avoided by the market. Investors didn't want to fund the technology category at all. The entire surgical-prosthetics industry was being downgraded in valuation models across the venture community.
Alcott had been the rising star of the domestic surgical-prosthetics market. Now he was a cautionary tale.
His phone rang again.
He picked it up.
"Alcott."
His assistant. Cautious, careful voice.
"Dr. Alcott, I just received a call from a company expressing interest in acquiring NeuraPath. I told them I would relay the message."
"An acquisition offer?" Alcott sat up. "In this market? Who's calling?"
The assistant hesitated. "Prism Sciences."
Silence.
Then Alcott actually laughed.
It wasn't a happy laugh. It was the laugh of a man who'd been outmaneuvered so completely that there was no remaining dignity in pretending otherwise.
The company that had built the product that had destroyed NeuraPath was now offering to buy NeuraPath's wreckage at a discount.
Alcott shook his head. Of course they were. From Prism Sciences' perspective, the math was straightforward. NeuraPath had assets that Prism Sciences could use: regulatory approvals already in progress, medical relationships, surgical training programs, a brand recognized in the prosthetics industry. A targeted acquisition at the bottom of NeuraPath's valuation cycle would give Prism Sciences a fully-staffed surgical-prosthetics subsidiary for less than the cost of building one from scratch.
This was the second act of corporate strategy. Phase one: destroy the competitor's market position. Phase two: buy the competitor's assets at distressed pricing.
Alcott opened his mouth to refuse on principle.
Then he closed it again.
NeuraPath was running out of runway. Refusing the acquisition would mean watching the company collapse, with every employee laid off and every patient relationship severed.
Selling to Prism Sciences would mean accepting that his career as an independent founder was over, but the work would continue. The medical relationships would persist. The patients would still receive care. NeuraPath as an institution would survive, just as a subsidiary.
The pragmatic answer was the obvious answer. Take the call.
"What's the contact information?" he asked his assistant.
The assistant read it back. Alcott wrote it down.
He stared at the number for a long time before picking up the phone.